Premium
Fluvoxamine and clomipramine in depressed patients A DOUBLE‐BLIND CLINICAL STUDY
Author(s) -
Klok C. J.,
Brouwer G. J.,
Praag H. M.,
Doogan D.
Publication year - 1981
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1981.tb00756.x
Subject(s) - clomipramine , fluvoxamine , anticholinergic , anxiolytic , psychology , anesthesia , clinical global impression , medicine , fluoxetine , psychiatry , serotonin , anxiety , receptor , alternative medicine , pathology , placebo
In a double‐blind study we compared fluvoxamine, a new selective serotonin re‐uptake inhibitor, with clomipramine. In 36 female in‐patients with vital depression, the antidepressant properties of fluvoxamine and clomipramine were studied. Eight patients did not complete the study. During a 4‐week treatment period the Hamilton‐, Zung‐, Clinical Global Impression‐ and Leyden ratings showed, apart from the last scale in the fluvoxamine group, significant improvement in both groups. In the latter scale, a statistically significant difference was found in favour of clomipramine. Additional anxiolytic‐sedative medication was required equally in both groups. CSF data in 10 patients are discussed. Non‐specific electrocardio‐graphic (ECG) repolarization disturbances were observed in both groups. Anticholinergic side effects were more prominent with clomipramine than with fluvoxamine; gastrointestinal symptoms and agitation were more prominent with fluvoxamine than with clomipramine. Fluvoxamine did not show particular advantages or disadvantages over clomipramine.